Lantern Pharma spins out Open-Medicine AI unit to commercialize multi-agent drug discovery platform

Reuters2026/08/03 11:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Lantern Pharma formed Open-Medicine AI as a separate company to commercialize its multi-agent drug-discovery platform previously branded withZeta.ai.
OMAI received commercial licenses to use Lantern’s withZeta.ai models, data, algorithms, related assets, personnel.
The structure follows terms set in Lantern’s May registered direct financing, positioning OMAI for independent funding and a separate valuation track.
Lantern set up an AI Center of Excellence in Bengaluru in Q1 2026, adding to Dallas operations to scale platform development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608030730BIZWIRE_USPR_____20260803_BW318492) on August 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Lantern Pharma spins out Open-Medicine AI unit to commercialize multi-agent drug discovery platform

You may also like

Crypto prices